Potential role of IL-13 in neuroprotection and cortical excitability regulation in multiple sclerosis

Multiple Sclerosis Journal

Volumn 17, Issue 11, 2011, Pages 1301-1312

  Rossi, S ^a,b   Mancino, R ^c   Bergami, A ^d   Mori, F ^a,b   Castelli, M ^a,b   De Chiara, V ^a,b   Studer, V ^a,b   Mataluni, G ^a,b   Sancesario, G ^c,e   Parisi, V ^f   Kusayanagi, H ^a,b   Bernardi, G ^a,b   Nucci, C ^c   Bernardini, S ^c,e   Martino, G ^d   Furlan, R ^d   Centonze, D ^a,b  

^a UNIVERSITY OF ROME TOR VERGATA   (Italy)

^b IRCCS FONDAZIONE SANTA LUCIA   (Italy)

^c UNIVERSITY OF ROME TOR VERGATA   (Italy)

^d SAN RAFFAELE HOSPITAL   (Italy)

^e TOR VERGATA UNIVERSITY HOSPITAL   (Italy)

^f IRCCS FONDAZIONE BIETTI   (Italy)

Author keywords

amyloid ; inflammation; neurodegeneration; optical coherence tomography; TMS

Indexed keywords

4 AMINOBUTYRATE AMINOTRANSFERASE; AMYLOID BETA PROTEIN[1-42]; INTERLEUKIN 10; INTERLEUKIN 13; INTERLEUKIN 4; INTERLEUKIN 5;

ADULT; ARTICLE; CEREBROSPINAL FLUID ANALYSIS; CLINICAL ARTICLE; CONTROLLED STUDY; FEMALE; HUMAN; MALE; MULTIPLE SCLEROSIS; NERVE CELL EXCITABILITY; NERVE DEGENERATION; NERVE FIBER; NEUROIMAGING; NEUROPATHOLOGY; NEUROPROTECTION; OPTICAL COHERENCE TOMOGRAPHY; PROTEIN DETERMINATION; PROTEIN FUNCTION; RETINA MACULA LUTEA; RETINA NERVE CELL; SYNAPSE; TRANSCRANIAL MAGNETIC STIMULATION; VISUAL ACUITY;

EID: 80655144773     PISSN: 13524585     EISSN: 14770970     Source Type: Journal    
DOI: 10.1177/1352458511410342     Document Type: Article

References (93)

1. Zeis T, Graumann U, Reynolds R, Schaeren-Wiemers N. Normal-appearing white matter in multiple sclerosis is in a subtle balance between inflammation and neuroprotection. Brain. 2008 ; 131: 288-303
2. Linker RA, Sendtner M, Gold R. Mechanisms of axonal degeneration in EAE lessons from CNTF and MHC I knockout mice. J Neurol Sci. 2005 ; 233: 167-172
3. Ivanov S, Lindén A. Interleukin-17 as a drug target in human disease. Trends Pharmacol Sci. 2009 ; 30: 95-103
4. Centonze D, Muzio L, Rossi S, Cavasinni F, De Chiara V, Bergami A, et al. Inflammation triggers synaptic alteration and degeneration in experimental autoimmune encephalomyelitis. J Neurosci. 2009 ; 29: 3442-3452
5. Rovaris M, Barnes D, Woodrofe N, du Boulay GH, Thorpe JW, Thompson AJ, et al. Patterns of disease activity in multiple sclerosis patients a study with quantitative gadolinium-enhanced brain MRI and cytokine measurement in different clinical subgroups. J Neurol. 1996 ; 243: 536-542
6. Wallström E, Khademi M, Andersson M, Olsson T. Increased numbers of mononuclear cells from blood and CSF expressing interferon-gamma mRNA in multiple sclerosis are from both the CD4 + and the CD8 + subsets. Eur J Neurol. 2000 ; 7: 71-76
7. Baraczka K, Pozsonyi T, Szüts I, Ormos G, Nékám K. Increased levels of tumor necrosis alpha and soluble vascular endothelial adhesion molecule-1 in the cerebrospinal fluid of patients with connective tissue diseases and multiple sclerosis. Acta Microbiol Immunol Hung. 2003 ; 50: 339-348
8. Mizuno T, Zhang G, Takeuchi H, Kawanokuchi J, Wang J, Sonobe Y, et al. Interferon-gamma directly induces neurotoxicity through a neuron specific, calcium-permeable complex of IFN-gamma receptor and AMPA GluR1 receptor. FASEB J. 2008 ; 22: 1797-1806
9. Froger N, Orellana JA, Calvo CF, Amigou E, Kozoriz MG, Naus CC, et al. Inhibition of cytokine-induced connexin43 hemichannel activity in astrocytes is neuroprotective. Mol Cell Neurosci. 2010 ; 45: 37-46
10. Tolosa L, Caraballo-Miralles V, Olmos G, Lladó J. TNF- potentiates glutamate-induced spinal cord motoneuron death via NF-κB. Mol Cell Neurosci. 2011 ; 46: 176-186
11. Garg SK, Kipnis J, Banerjee R. IFN-gamma and IL-4 differentially shape metabolic responses and neuroprotective phenotype of astrocytes. J Neurochem. 2009 ; 108: 1155-1166
12. S-Rózsa K, Rubakhin SS, Szücs A, Hughes TK, Stefano GB. Opposite effects of interleukin-2 and interleukin-4 on GABA-induced inward currents of dialysed Lymnaea neurons. Gen Pharmacol. 1997 ; 29: 73-77
13. Zhou Z, Peng X, Insolera R, Fink DJ, Mata M. IL-10 promotes neuronal survival following spinal cord injury. Exp Neurol. 2009 ; 220: 183-190
14. Nakajima K, Tohyama Y, Maeda S, Kohsaka S, Kurihara T. Neuronal regulation by which microglia enhance the production of neurotrophic factors for GABAergic, catecholaminergic, and cholinergic neurons. Neurochem Int. 2007 ; 50: 807
15. Shin WH, Lee DY, Park KW, Kim SU, Yang MS, Joe EH, et al. Microglia expressing interleukin-13 undergo cell death and contribute to neuronal survival in vivo. Glia. 2004 ; 46: 142-152
16. Sinha S, Kaler LJ, Proctor TM, Teuscher C, Vandenbark AA, Offner H. IL-13-mediated gender difference in susceptibility to autoimmune encephalomyelitis. J Immunol. 2008 ; 180: 2679-2685
17. Bjartmar C, Kinkel RP, Kidd G, Rudick RA, Trapp BD. Axonal loss in normal-appearing white matter in a patient with acute MS. Neurology. 2001 ; 57: 1248-1252
18. Filippi M, Bozzali M, Rovaris M, Gonen O, Kesavadas C, et al. Evidence for widespread axonal damage at the earliest clinical stage of multiple sclerosis. Brain. 2003 ; 126: 433-437
19. Seehusen F, Baumgärtner W. Axonal pathology and loss precede demyelination and accompany chronic lesions in a spontaneously occurring animal model of multiple sclerosis. Brain Pathol. 2010 ; 20: 551-559
20. Qureshi GA, Baig MS. Quantitation of free amino acids in biological samples by high-performance liquid chromatography. Application of the method in evaluating amino acid levels in cerebrospinal fluid and plasma of patients with multiple sclerosis. J Chromatogr. 1988 ; 459: 237-244
21. Srinivasan R, Sailasuta N, Hurd R, Nelson S, Pelletier D. Evidence of elevated glutamate in multiple sclerosis using magnetic resonance spectroscopy at 3T. Brain. 2005 ; 128: 1016-1025
22. Cianfoni A, Niku S, Imbesi SG. Metabolite findings in tumefactive demyelinating lesions utilizing short echo time proton magnetic resonance spectroscopy. AJNR Am J Neuroradiol. 2007 ; 28: 272-277
23. Newcombe J, Uddin A, Dove R, Patel B, Turski L, et al. Glutamate receptor expression in multiple sclerosis lesions. Brain Pathol. 2008 ; 18: 52-61
24. Rossi S, De Chiara V, Furlan R, Musella A, Cavasinni F, et al. Abnormal activity of the Na/Ca exchanger enhances glutamate transmission in experimental autoimmune encephalomyelitis. Brain Behav Immun. 2010 ; 24: 1379-1385
25. Rossi S, Muzio L, De Chiara V, Grasselli G, Musella A, et al. Impaired striatal GABA transmission in experimental autoimmune encephalomyelitis. Brain Behav Immun. 2010 ;:
26. Blennow K, Hampel H, Weiner M, Zetterberg H. Cerebrospinal fluid and plasma biomarkers in Alzheimer disease. Nat Rev Neurol. 2010 ; 6: 131-144
27. Reiniger L, Lukic A, Linehan J, Rudge P, Collinge J, et al. Tau, prions and Abeta: The triad of neurodegeneration. Acta Neuropathol. 2011 ; 121: 5-20
28. Mori F, Rossi S, Sancesario G, Codecà C, Mataluni G, et al. Cognitive and cortical plasticity deficits correlate with altered amyloid-β CSF levels in multiple sclerosis. Neuropsychopharmacology. 2011 ; 36: 559-568
29. Lassmann H. Mechanisms of neurodegeneration shared between multiple sclerosis and Alzheimers disease. J Neural Transm. 2011 ;:
30. Gordon-Lipkin E, Chodkowski B, Reich DS, Smith SA, Pulicken M, et al. Retinal nerve fiber layer is associated with brain atrophy in multiple sclerosis. Neurology. 2007 ; 69: 1603-1609
31. Grazioli E, Zivadinov R, Weinstock-Guttman B, Lincoff N, Baier M, et al. Retinal nerve fiber layer thickness is associated with brain MRI outcomes in multiple sclerosis. J Neurol Sci. 2008 ; 268: 12-17
32. Frohman EM, Fujimoto JG, Frohman TC, Calabresi PA, Cutter G, Balcer LJ. Optical coherence tomography: A window into the mechanisms of multiple sclerosis. Nat Clin Pract Neurol. 2008 ; 4: 664-675
33. Zaveri MS, Conger A, Salter A, Frohman TC, Galetta SL, et al. Retinal imaging by laser polarimetry and optical coherence tomography evidence of axonal degeneration in multiple sclerosis. Arch Neurol. 2008 ; 65: 924-928
34. McDonald WI, Compston A, Edan G, Goodkin D, Hartung HP, et al. Recommended diagnostic criteria for multiple sclerosis: Guidelines from the International Panel on the diagnosis of multiple sclerosis. Ann Neurol. 2001 ; 50: 121-127
35. Polman CH, Reingold SC, Edan G, Filippi M, Hartung HP, et al. Diagnostic criteria for multiple sclerosis: 2005 revisions to the McDonald Criteria. Ann Neurol. 2005 ; 58: 840-846
36. Centonze D, Bari M, Rossi S, Prosperetti C, Furlan R, et al. The endocannabinoid system is dysregulated in multiple sclerosis and in experimental autoimmune encephalomyelitis. Brain. 2007 ; 130: 2543-2553
37. Sancesario GM, Esposito Z, Nuccetelli M, Bernardini S, Sorge R, et al. Abeta1-42 detection in CSF of Alzheimers disease is influenced by temperature: Indication of reversible Abeta1-42 aggregation?. Exp Neurol. 2010 ; 223: 371-376
38. Kurtzke JF. Rating neurologic impairment in multiple sclerosis: An Expanded Disability Status Scale (EDSS). Neurology. 1983 ; 33: 1444-1452
39. Kujirai T, Caramia MD, Rothwell JC, Day BL, Thompson PD, et al. Corticocortical inhibition in human motor cortex. J Physiol. 1993 ; 471: 501-519
40. Ziemann U, Tergau F, Wischer S, Hildebrandt J, Paulus W. Pharmacological control of facilitatory I-wave interaction in the human motor cortex. A paired transcranial magnetic stimulation study. Electroencephalogr Clin Neurophysiol. 1998 ; 109: 321-330
41. Valls-Solé J, Pascual-Leone A, Wassermann EM, Hallett M. Human motor evoked responses to paired transcranial magnetic stimuli. Electroencephalogr Clin Neurophysiol. 1992 ; 85: 355-364
42. Oldfield RC. The assessment and analysis of handedness: The Edinburgh inventory. Neuropsychologia. 1971 ; 9: 97-113
43. Rothwell JC. Techniques and mechanisms of action of transcranial stimulation of the human motor cortex. J Neurosci Methods. 1997 ; 74: 113-122
44. Hanajima R, Ugawa Y, Terao Y, Enomoto H, Shiio Y, et al. Mechanisms of intracortical I-wave facilitation elicited with paired-pulse magnetic stimulation in humans. J Physiol. 2002 ; 538: 253-261
45. Frohman E, Costello F, Zivadinov R, Stuve O, Conger A, et al. Optical coherence tomography in multiple sclerosis. Lancet Neurol. 2006 ; 5: 853-863
46. Barkhof F, Calabresi PA, Miller DH, Reingold SC. Imaging outcomes for neuroprotection and repair in multiple sclerosis trials. Nat Rev Neurol. 2009 ; 5: 256-266
47. Burkholder BM, Osborne B, Loguidice MJ, Bisker E, Frohman TC, et al. Macular volume determined by optical coherence tomography as a measure of neuronal loss in multiple sclerosis. Arch Neurol. 2009 ; 66: 1366-1372
48. Baier ML, Cutter GR, Rudick RA, Miller D, Cohen JA, et al. Low-contrast letter acuity testing captures visual dysfunction in patients with multiple sclerosis. Neurology. 2005 ; 64: 992-995
49. Balcer LJ, Galetta SL, Calabresi PA, Confavreux C, Giovannoni G, et al. Natalizumab reduces visual loss in patients with relapsing multiple sclerosis. Neurology. 2007 ; 68: 1299-1304
50. Fisniku LK, Chard DT, Jackson JS, Anderson VM, Altmann DR, et al. Gray matter atrophy is related to long-term disability in multiple sclerosis. Ann Neurol. 2008 ; 64: 247-254
51. Centonze D, Muzio L, Rossi S, Furlan R, Bernardi G, Martino G. The link between inflammation, synaptic transmission and neurodegeneration in multiple sclerosis. Cell Death Differ. 2010 ; 17: 1083-1091
52. Compston A, Coles A. Multiple sclerosis. Lancet. 2008 ; 372: 1502-1517
53. Trapp BD, Nave KA. Multiple sclerosis: An immune or neurodegenerative disorder?. Annu Rev Neurosci. 2008 ; 31: 247-269
54. Allan SM, Tyrrell PJ, Rothwell NJ. Interleukin-1 and neuronal injury. Nat Rev Immunol. 2005 ; 5: 629-640
55. Babcock AA, Kuziel WA, Rivest S, Owens T. Chemokine expression by glial cells directs leukocytes to sites of axonal injury in the CNS. J Neurosci. 2003 ; 23: 7922-7930
56. Laing JM, Aurelian L. DeltaRR vaccination protects from KA-induced seizures and neuronal loss through ICP10PK-mediated modulation of the neuronal-microglial axis. Genet Vaccines Ther. 2008 ; 6: 1
57. Wiesemann E, Klatt J, Sönmez D, Blasczyk R, Heidenreich F, Windhagen A. Glatiramer acetate (GA) induces IL-13/IL-5 secretion in naive T cells. J Neuroimmunol. 2001 ; 119: 137-144
58. Wiesemann E, Sönmez D, Heidenreich F, Windhagen A. Interferon-beta increases the stimulatory capacity of monocyte-derived dendritic cells to induce IL-13, IL-5 and IL-10 in autologous T-cells. J Neuroimmunol. 2002 ; 123: 160-169
59. Wiesemann E, Klatt J, Wenzel C, Heidenreich F, Windhagen A. Correlation of serum IL-13 and IL-5 levels with clinical response to glatiramer acetate in patients with multiple sclerosis. Clin Exp Immunol. 2003 ; 133: 454-460
60. Sanna A, Fois ML, Arru G, Huang YM, Link H, et al. Glatiramer acetate reduces lymphocyte proliferation and enhances IL-5 and IL-13 production through modulation of monocyte-derived dendritic cells in multiple sclerosis. Clin Exp Immunol. 2006 ; 143: 357-362
61. Nicoletti F, Marco RD, Patti A, Nicoletti C, Leonardi E, et al. The anti-inflammatory cytokine interleukin-13 is not detectable in the circulation of multiple sclerosis patients and is not inducible by interferon-beta1b treatment, that neither modifies its ex vivo secretion from peripheral blood mononuclear cells. Autoimmunity. 2000 ; 32: 265-270
62. Ochi H, Osoegawa M, Wu XM, Minohara M, Horiuchi I, et al. Increased IL-13 but not IL-5 production by CD4-positive T cells and CD8-positive T cells in multiple sclerosis during relapse phase. J Neurol Sci. 2002 ; 201: 45-51
63. Bartosik-Psujek H, Stelmasiak Z. Correlations between IL-4, IL-12 levels and CCL2, CCL5 levels in serum and cerebrospinal fluid of multiple sclerosis patients. J Neural Transm. 2005 ; 112: 797-803
64. Mattsson N, Axelsson M, Haghighi S, Malmeström C, Wu G, et al. Reduced cerebrospinal fluid BACE1 activity in multiple sclerosis. Mult Scler. 2009 ; 15: 448-454
65. Perrin RJ, Fagan AM, Holtzman DM. Multimodal techniques for diagnosis and prognosis of Alzheimers disease. Nature. 2009 ; 461: 916-922
66. Fan LW, Mitchell HJ, Tien LT, Rhodes PG, Cai Z. Interleukin-1beta-induced brain injury in the neonatal rat can be ameliorated by alpha-phenyl-n-tert- butyl-nitrone. Exp Neurol. 2009 ; 220: 143-153
67. Kong Q, Peterson TS, Baker O, Stanley E, Camden J, et al. Interleukin-1beta enhances nucleotide-induced and alpha-secretase-dependent amyloid precursor protein processing in rat primary cortical neurons via up-regulation of the P2Y(2) receptor. J Neurochem. 2009 ; 109: 1300-1310
68. Shimizu E, Kawahara K, Kajizono M, Sawada M, Nakayama H. IL-4-induced selective clearance of oligomeric beta-amyloid peptide(1-42) by rat primary type 2 microglia. J Immunol. 2008 ; 181: 6503-6513
69. Costello F, Hodge W, Pan YI, Freedman M, DeMeulemeester C. Differences in retinal nerve fiber layer atrophy between multiple sclerosis subtypes. J Neurol Sci. 2009 ; 281: 74-79
70. Offner H, Subramanian S, Wang C, Afentoulis M, Vandenbark AA, et al. Treatment of passive experimental autoimmune encephalomyelitis in SJL mice with a recombinant TCR ligand induces IL-13 and prevents axonal injury. J Immunol. 2005 ; 175: 4103-4111
71. Ochoa-Repáraz J, Rynda A, Ascón MA, Yang X, Kochetkova I, et al. IL-13 production by regulatory T cells protects against experimental autoimmune encephalomyelitis independently of autoantigen. J Immunol. 2008 ; 181: 954-968
72. Walker DG, Dalsing-Hernandez JE, Campbell NA, Lue LF. Decreased expression of CD200 and CD200 receptor in Alzheimers disease: A potential mechanism leading to chronic inflammation. Exp Neurol. 2009 ; 215: 5-19
73. Koning N, van Eijk M, Pouwels W, Brouwer MS, Voehringer D, et al. Expression of the inhibitory CD200 receptor is associated with alternative macrophage activation. J Innate Immun. 2010 ; 2: 195-200
74. Dick AD, Broderick C, Forrester JV, Wright GJ. Distribution of OX2 antigen and OX2 receptor within retina. Invest Ophthalmol Vis Sci. 2001 ; 42: 170-176
75. Jenmalm MC, Cherwinski H, Bowman EP, Phillips JH, Sedgwick JD. Regulation of myeloid cell function through the CD200 receptor. J Immunol. 2006 ; 176: 191-199
76. Koning N, Swaab DF, Hoek RM, Huitinga I. Distribution of the immune inhibitory molecules CD200 and CD200R in the normal central nervous system and multiple sclerosis lesions suggests neuron-glia and glia-glia interactions. J Neuropathol Exp Neurol. 2009 ; 68: 159-167
77. Meuth SG, Simon OJ, Grimm A, Melzer N, Herrmann AM, et al. CNS inflammation and neuronal degeneration is aggravated by impaired CD200-CD200R-mediated macrophage silencing. J Neuroimmunol. 2008 ; 194: 62-69
78. Chitnis T, Imitola J, Wang Y, Elyaman W, Chawla P, et al. Elevated neuronal expression of CD200 protects Wlds mice from inflammation-mediated neurodegeneration. Am J Pathol. 2007 ; 170: 1695-1712
79. Koning N, Bö L, Hoek RM, Huitinga I. Downregulation of macrophage inhibitory molecules in multiple sclerosis lesions. Ann Neurol. 2007 ; 62: 504-514
80. Lu XG, Zhang JJ, Zhang CD, Liu R, Zheng L, et al. Altered regulation of CD200 receptor in monocyte-derived macrophages from individuals with Parkinsons disease. Neurochem Res. 2010 ; 35: 540-547
81. Rudick RA, Cutter G, Baier M, Fisher E, Dougherty D, et al. Use of the Multiple Sclerosis Functional Composite to predict disability in relapsing MS. Neurology. 2001 ; 56: 1324-1330
82. Rudick RA, Cutter G, Reingold S. The Multiple Sclerosis Functional Composite: A new clinical outcome measure for multiple sclerosis trials. Mult Scler. 2002 ; 8: 359-365
83. Forder JP, Tymianski M. Postsynaptic mechanisms of excitotoxicity: Involvement of postsynaptic density proteins, radicals, and oxidant molecules. Neuroscience. 2009 ; 158: 293-300
84. Stover JF, Lowitzsch K, Kempski OS. Cerebrospinal fluid hypoxanthine, xanthine and uric acid levels may reflect glutamate-mediated excitotoxicity in different neurological diseases. Neurosci Lett. 1997 ; 238: 25-28
85. Sarchielli P, Greco L, Floridi A, Floridi A, Gallai V. Excitatory amino acids and multiple sclerosis: Evidence from cerebrospinal fluid. Arch Neurol. 2003 ; 60: 1082-1088
86. Plaut GS. Effectiveness of amantadine in reducing relapses in multiple sclerosis. J R Soc Med. 1987 ; 80: 91-93
87. Pitt D, Werner P, Raine CS. Glutamate excitotoxicity in a model of multiple sclerosis. Nat Med. 2000 ; 6: 67-70
88. Smith T, Groom A, Zhu B, Turski L. Autoimmune encephalomyelitis ameliorated by AMPA antagonists. Nat Med. 2000 ; 6: 62-66
89. Bhat R, Axtell R, Mitra A, Miranda M, Lock C, et al. Inhibitory role for GABA in autoimmune inflammation. Proc Natl Acad Sci USA. 2010 ; 107: 2580-2585
90. Dutta R, McDonough J, Yin X, Peterson J, Chang A, et al. Mitochondrial dysfunction as a cause of axonal degeneration in multiple sclerosis patients. Ann Neurol. 2006 ; 59: 478-489
91. Clements RJ, McDonough J, Freeman EJ. Distribution of parvalbumin and calretinin immunoreactive interneurons in motor cortex from multiple sclerosis post-mortem tissue. Exp Brain Res. 2008 ; 187: 459-465
92. Caramia MD, Palmieri MG, Desiato MT, Boffa L, Galizia P, et al. Brain excitability changes in the relapsing and remitting phases of multiple sclerosis: A study with transcranial magnetic stimulation. Clin Neurophysiol. 2004 ; 115: 956-965
93. Sucher NJ, Lipton SA, Dreyer EB. Molecular basis of glutamate toxicity in retinal ganglion cells. Vision Res. 1997 ; 37: 3483-3493